Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase 1/2 1

Status

Completed 5Not yet recruiting 2Recruiting 1

Sponsor Class

OTHER 4INDUSTRY 3OTHER_GOV 1

Study Type

Interventional 6Observational 2

Sponsor

Cancer Type

Tumor-Agnostic 3Thoracic 2Sarcoma 1Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 18Carcinoma, Hepatocellular 9Neoplasms 8Melanoma 7Squamous Cell Carcinoma of Head and Neck 6Nasopharyngeal Carcinoma 6Triple Negative Breast Neoplasms 5Esophageal Neoplasms 5Neoplasm Metastasis 4Esophageal Squamous Cell Carcinoma 4Colonic Neoplasms 4Recurrence 3Rectal Neoplasms 3Pancreatic Neoplasms 3Lung Neoplasms 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Stomach Neoplasms 2Solid Cancers 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Ovarian Neoplasms 2Gastric / Gastroesophageal Junction Adenocarcinoma 2EBV-associated Tumors 2Cholangiocarcinoma 2Breast Neoplasms 2Bites and Stings 2Biliary Tract Neoplasms 2Advanced Solid Tumors 2

Interventions

pembrolizumab 90Blood Specimen Collection 41Cyclophosphamide 37Bevacizumab 36Nivolumab 35Standard of Care 32Carboplatin 31Surveys and Questionnaires 29Paclitaxel 27atezolizumab 25Exercise 25Pemetrexed 24Gemcitabine 23Cisplatin 23Fluorouracil 22Radiotherapy 20Leucovorin 20Dexamethasone 20Docetaxel 19Oxaliplatin 18Rituximab 16Irinotecan 16Cetuximab 16dostarlimab 15Drug Therapy 15Doxorubicin 15Ipilimumab 14Biopsy 14130-nm albumin-bound paclitaxel 14fludarabine 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Neoplasms × Immune Checkpoint Inhibitors × 1 year × Clear all
NCT07593053 2026-05-22

PIPO

Vall d'Hebron Institute of Oncology

Completed
586 enrolled
Tumor-Agnostic

Neoplasms

NCT07192926 2026-02-20

SARCO-CTI

Ankara Etlik City Hospital

Completed
131 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Neoplasms, Sarcopenia

NCT06524570 2026-02-18

iFOCUS

UMC Utrecht

Phase 1 Recruiting
24 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT07277777 2026-01-06

125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant Tumors

Jinan Military General Hospital

Phase 2 Not yet recruiting
90 enrolled

Neoplasms, Recurrence

NCT04417465 2025-09-25

First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

AbbVie

Phase 1 Completed
101 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT04681131 2025-09-25

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

BioAtla, Inc.

Phase 2 Completed
85 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03425279 2025-09-23

CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

BioAtla, Inc.

Phase 1/2 Completed
245 enrolled
Sarcoma

Neoplasms, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT07142200 2025-08-26

DECIDING

RenJi Hospital

Phase 2 Not yet recruiting
45 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡